BUSINESS COMBINATIONS AND ACQUISITIONS (Details) (USD $)	3 Months Ended		9 Months Ended				3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		1 Months Ended	3 Months Ended	9 Months Ended			0 Months Ended				1 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013 Tedizolid phosphate	Sep. 30, 2013 Research and development expense	Sep. 30, 2012 Research and development expense	Sep. 30, 2013 Research and development expense	Sep. 30, 2012 Research and development expense	Sep. 30, 2013 Selling, general and administrative expense	Sep. 30, 2012 Selling, general and administrative expense	Sep. 30, 2013 Selling, general and administrative expense	Sep. 30, 2012 Selling, general and administrative expense	Sep. 30, 2013 Trius Therapeutics, Inc.	Sep. 30, 2013 Trius Therapeutics, Inc.	Sep. 30, 2013 Trius Therapeutics, Inc.	Sep. 30, 2012 Trius Therapeutics, Inc.	Sep. 11, 2013 Trius Therapeutics, Inc. right	Sep. 11, 2013 Trius Therapeutics, Inc. Tedizolid phosphate	Sep. 30, 2013 Trius Therapeutics, Inc. Minimum	Sep. 30, 2013 Trius Therapeutics, Inc. Maximum	Sep. 11, 2013 Trius Therapeutics, Inc. Maximum	Sep. 30, 2013 Trius Therapeutics, Inc. Research and development expense	Sep. 30, 2013 Trius Therapeutics, Inc. Research and development expense	Sep. 30, 2013 Trius Therapeutics, Inc. Research and development expense	Sep. 30, 2013 Trius Therapeutics, Inc. Selling, general and administrative expense	Sep. 30, 2013 Trius Therapeutics, Inc. Selling, general and administrative expense	Sep. 30, 2013 Trius Therapeutics, Inc. Selling, general and administrative expense
BUSINESS COMBINATIONS AND ACQUISITIONS
Percentage of issued and outstanding shares purchased																			100.00%
Tender offer purchase price of outstanding common stock of acquiree (in dollars per share)																			$ 13.50
Number of contingent value rights receivable by stockholders of acquiree																			1
Maximum additional cash payment per share (in dollars per share)																							$ 2.00
Total Acquisition-Date Fair Value
Cash transferred, including transaction costs																			$ 694,426,000
Contingent consideration (CVRs)																			4,603,000
Total consideration transferred																			699,029,000
Transaction costs paid on behalf of acquiree																			13,700,000
Charges for stock-based compensation	7,965,000	6,752,000	24,104,000	19,244,000			2,816,000	2,371,000	8,583,000	6,724,000	5,029,000	4,248,000	15,147,000	12,215,000	24,000,000	24,000,000	24,000,000							12,400,000	12,400,000	12,400,000	11,600,000	11,600,000	11,600,000
Undiscounted contingent consideration																					0	108,400,000
Estimated fair values of the assets acquired and liabilities assumed
Cash																			22,697,000
Investments																			39,513,000
IPR&D	931,700,000		931,700,000		272,700,000	659,000,000													659,000,000
Deferred tax assets																			92,567,000
Goodwill																			159,442,000
Other assets acquired																			5,522,000
Total assets acquired																			978,741,000
Deferred tax liabilities																			(249,353,000)
Other liabilities assumed																			(30,359,000)
Total liabilities assumed																			(279,712,000)
Total net assets acquired																			699,029,000
Discount rate for determining fair value of acquired asset (as a percent)																	8.00%			9.50%
Operating loss of acquiree included in the income statement of combined entity															4,800,000	4,800,000	4,800,000
Transaction costs															10,200,000	10,200,000	10,200,000
Supplemental unaudited pro forma information
Total revenues, net																	754,701,000	689,440,000
Net (loss) income																	$ (27,912,000)	$ 52,214,000